X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
osteoprotegerin (2340) 2340
humans (2151) 2151
index medicus (2058) 2058
animals (1826) 1826
female (1281) 1281
male (1233) 1233
mice (1144) 1144
osteoporosis (933) 933
osteoprotegerin - metabolism (715) 715
endocrinology & metabolism (686) 686
osteoclasts - drug effects (680) 680
rank ligand - metabolism (680) 680
middle aged (673) 673
receptor activator (665) 665
rankl (662) 662
cells, cultured (661) 661
expression (600) 600
rats (537) 537
rank ligand (529) 529
differentiation (494) 494
bone (491) 491
osteoclasts - metabolism (486) 486
adult (481) 481
aged (479) 479
osteoprotegerin ligand (451) 451
cells (448) 448
osteoblasts - drug effects (448) 448
cell differentiation - drug effects (435) 435
osteoclasts - cytology (429) 429
osteoblasts - metabolism (428) 428
osteoprotegerin - genetics (423) 423
kappa-b ligand (413) 413
cell biology (412) 412
osteoclast differentiation (406) 406
bone resorption (404) 404
musculoskeletal diseases (399) 399
in-vitro (397) 397
osteoclastogenesis (396) 396
osteoclasts (396) 396
receptor activator of nuclear factor-kappa b (386) 386
osteoblasts (369) 369
gene expression (366) 366
postmenopausal women (366) 366
analysis (359) 359
inflammation (358) 358
bones (356) 356
receptors, tumor necrosis factor (356) 356
osteoprotegerin - blood (352) 352
biochemistry & molecular biology (343) 343
osteoclast (336) 336
trance protein (334) 334
rheumatology (327) 327
bone-resorption (326) 326
rank ligand - genetics (324) 324
cytokines (320) 320
ligand (309) 309
osteogenesis - drug effects (298) 298
orthopedics (287) 287
research (286) 286
bone and bones - metabolism (284) 284
apoptosis (283) 283
bone density - drug effects (282) 282
oncology (281) 281
mice, inbred c57bl (276) 276
dentistry, oral surgery & medicine (274) 274
cell line (273) 273
dentistry (273) 273
bone density (265) 265
rna, messenger - metabolism (264) 264
density (260) 260
medicine, research & experimental (255) 255
resorption (255) 255
opg (254) 254
activation (253) 253
physiological aspects (253) 253
rheumatoid-arthritis (251) 251
proteins (247) 247
biomarkers - blood (245) 245
immunology (243) 243
osteoblasts - cytology (243) 243
biocompatibility (242) 242
bone loss (239) 239
disease (238) 238
dose-response relationship, drug (238) 238
ligands (234) 234
research article (230) 230
medicine & public health (228) 228
pharmacology & pharmacy (228) 228
signal transduction (228) 228
mineral density (227) 227
risk factors (227) 227
gene-expression (225) 225
disease models, animal (223) 223
enzyme-linked immunosorbent assay (222) 222
osteoclasts - physiology (221) 221
bone and bones - drug effects (218) 218
gene expression regulation - drug effects (216) 216
time factors (216) 216
bone-mineral density (214) 214
metabolism (213) 213
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3689) 3689
Chinese (57) 57
Japanese (9) 9
Spanish (8) 8
German (6) 6
Polish (6) 6
French (3) 3
Russian (3) 3
Danish (1) 1
Dutch (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Periodontology, ISSN 0022-3492, 08/2013, Volume 84, Issue 8, pp. 1145 - 1157
Background: Simvastatin is a cholesterol‐lowering drug whose pleiotropic effects may have a therapeutic impact on bone. This study evaluates the effect of... 
hydroxymethylglutaryl‐CoA reductase inhibitors | inflammation | Alveolar bone loss | periodontitis | Inflammation | Hydroxymethylglutaryl-CoA reductase inhibitors | Periodontitis | OVARIECTOMIZED RATS | STATINS | IN-VITRO | METABOLISM | DENTISTRY, ORAL SURGERY & MEDICINE | NITRIC-OXIDE | hydroxymethylglutaryl-CoA reductase inhibitors | MEVALONATE PATHWAY | KAPPA-B LIGAND | PROTEIN PRENYLATION | Interleukin-1beta - drug effects | Simvastatin - therapeutic use | Bone Morphogenetic Protein 2 - drug effects | Rats, Wistar | Matrix Metalloproteinase 8 - drug effects | Alveolar Bone Loss - prevention & control | Receptor Activator of Nuclear Factor-kappa B - drug effects | RANK Ligand - drug effects | Malondialdehyde - analysis | Alanine Transaminase - drug effects | Gingiva - drug effects | Glutathione - drug effects | Anti-Inflammatory Agents - therapeutic use | Female | Osteoprotegerin - drug effects | Interleukin-10 - analysis | Nitrates - analysis | Peroxidase - drug effects | Matrix Metalloproteinase 1 - drug effects | Nitric Oxide Synthase Type II - drug effects | Rats | Aspartate Aminotransferases - drug effects | Alkaline Phosphatase - drug effects | Periodontitis - prevention & control | Antioxidants - therapeutic use | Animals | Tumor Necrosis Factor-alpha - drug effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Nitrites - analysis | Oxidative Stress - drug effects
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 07/2011, Volume 26, Issue 7, pp. 1517 - 1532
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2011, Volume 6, Issue 10, p. e25900
Sclerostin is a product of mature osteocytes embedded in mineralised bone and is a negative regulator of bone mass and osteoblast differentiation. While... 
MESSENGER-RNA | BONE MORPHOGENETIC PROTEIN | MULTIDISCIPLINARY SCIENCES | HUMAN PRIMARY OSTEOBLASTS | RECEPTOR ACTIVATOR | MECHANICAL STIMULATION | PARATHYROID-HORMONE | CELL-DIFFERENTIATION | WNT | EXPRESSION | KAPPA-B LIGAND | Osteocytes - drug effects | RANK Ligand - metabolism | Apoptosis - drug effects | Humans | Tartrate-Resistant Acid Phosphatase | Osteoclasts - cytology | Cell Differentiation - genetics | Acid Phosphatase - metabolism | Isoenzymes - metabolism | Adult | Osteoblasts - cytology | Bone Morphogenetic Proteins - pharmacology | Osteogenesis - genetics | Cell Survival - drug effects | Calcification, Physiologic - drug effects | Osteocytes - metabolism | Osteoblasts - drug effects | Osteocytes - cytology | Osteogenesis - drug effects | Cells, Cultured | Genetic Markers | Recombinant Proteins - pharmacology | Osteoclasts - metabolism | Gene Expression Regulation - drug effects | RANK Ligand - genetics | Animals | Signal Transduction - drug effects | Cell Differentiation - drug effects | Mice | Osteoblasts - metabolism | Osteoclasts - drug effects | Bones | RNA | Gene expression | Density | Genes | Homeostasis | Osteocytes | Leukocytes (mononuclear) | SOST protein | Biology | Kinases | Osteoprotegerin | Monoculture | Ethics | Genotype & phenotype | Splenocytes | Peripheral blood mononuclear cells | Tumor necrosis factor-TNF | Biocompatibility | TRANCE protein | Discipline | Recombinant | Cytokines | Caspase | Cultures | Bone mass | Osteoblastogenesis | Low density lipoprotein receptors | Osteoclasts | Acid phosphatase (tartrate-resistant) | Bone | Apoptosis
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2012, Volume 109, Issue 8, pp. 3143 - 3148
Journal Article
Nature medicine, ISSN 1078-8956, 11/2014, Volume 20, Issue 11, pp. 1279 - 1288
The WNT16 locus is a major determinant of cortical bone thickness and nonvertebral fracture risk in humans. The disability, mortality and costs caused by... 
MEDICINE, RESEARCH & EXPERIMENTAL | CELLS | ACTIVATION | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BETA-CATENIN | CELL BIOLOGY | MINERAL DENSITY | SOST GENE | MASS | RECEPTOR-RELATED PROTEIN-5 | GENOME-WIDE | DIFFERENTIATION | Osteocytes - drug effects | Humans | Wnt Proteins - deficiency | RNA, Messenger - metabolism | Wnt Proteins - metabolism | Cell Lineage - drug effects | Fractures, Bone - genetics | Cell Differentiation - genetics | RANK Ligand - pharmacology | Wnt Proteins - genetics | Skull - pathology | Gene Deletion | Organ Size - genetics | Osteogenesis - genetics | Cell Line | Osteoclasts - pathology | Disease Susceptibility | Osteocytes - metabolism | Mice, Inbred C57BL | Osteoblasts - drug effects | Osteogenesis - drug effects | RNA, Messenger - genetics | Cells, Cultured | Signal Transduction - genetics | Osteoclasts - metabolism | Fractures, Bone - metabolism | Aging - pathology | Gene Expression Regulation - drug effects | Osteoblasts - pathology | Organ Size - drug effects | Animals | Signal Transduction - drug effects | Cell Differentiation - drug effects | Osteocytes - pathology | Fractures, Bone - pathology | Osteoprotegerin - metabolism | Osteoblasts - metabolism | Fractures, Bone - prevention & control | Osteoclasts - drug effects | Physiological aspects | Fractures | Research | Wnt proteins | Analysis | Osteoclasts (Biology) | Osteoporosis | Signal transduction | Bones | Glycoproteins | Porosity | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 02/2009, Volume 24, Issue 2, pp. 182 - 195
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 01/2010, Volume 25, Issue 1, pp. 72 - 81
Journal Article
Osteoarthritis and Cartilage, ISSN 1063-4584, 2015, Volume 24, Issue 1, pp. 178 - 187
Summary Objective To determine whether mandibular condylar cartilage degradation induced by experimentally abnormal occlusion could be ameliorated via systemic... 
Rheumatology | Strontium | Cartilage | Subchondral bone | NBD (NEMO-binding domain) peptide | Temporomandibular joint | Osteoarthritis | Dental occlusion | TGF-BETA | CHONDROCYTES | BLOCKS OSTEOCLASTOGENESIS | RHEUMATOLOGY | TRABECULAR BONE | SUBCHONDRAL BONE LOSS | RANELATE | INHIBITION | TEMPOROMANDIBULAR-JOINT | ORTHOPEDICS | NF-KAPPA-B | KNEE OSTEOARTHRITIS | Immunohistochemistry | RANK Ligand - metabolism | Collagen Type II - drug effects | Tumor Necrosis Factor-alpha - genetics | ADAM Proteins - drug effects | Interleukin-1beta - genetics | RNA, Messenger - metabolism | Proteoglycans - drug effects | Collagen Type II - metabolism | Cartilage, Articular - metabolism | Interleukin-1beta - metabolism | Malocclusion | Receptor Activator of Nuclear Factor-kappa B - metabolism | Aggrecans - drug effects | Real-Time Polymerase Chain Reaction | ADAMTS5 Protein | NF-KappaB Inhibitor alpha | Proteoglycans - metabolism | I-kappa B Proteins - drug effects | Aggrecans - metabolism | ADAM Proteins - metabolism | Tumor Necrosis Factor-alpha - drug effects | Strontium - pharmacology | Mice | Osteoprotegerin - metabolism | ADAM Proteins - genetics | Interleukin-1beta - drug effects | Tumor Necrosis Factor-alpha - metabolism | I-kappa B Proteins - metabolism | I-kappa B Proteins - genetics | Receptor Activator of Nuclear Factor-kappa B - drug effects | Transcription Factor RelA - genetics | RANK Ligand - drug effects | Mandibular Condyle - pathology | Osteoprotegerin - genetics | Female | Mandibular Condyle - drug effects | Osteoprotegerin - drug effects | RNA, Messenger - drug effects | Mice, Inbred C57BL | Aggrecans - genetics | Osteoclasts - metabolism | Collagen Type II - genetics | Peptides - pharmacology | RANK Ligand - genetics | Animals | Transcription Factor RelA - metabolism | Receptor Activator of Nuclear Factor-kappa B - genetics | Transcription Factor RelA - drug effects | Cartilage, Articular - drug effects | Mandibular Condyle - metabolism | Dental Occlusion | Osteoclasts - drug effects | Peptides
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 09/2013, Volume 28, Issue 9, pp. 1936 - 1949
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9773, pp. 1276 - 1287
Summary Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. With an... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | SCLEROSTIN ANTIBODY | BONE-MINERAL DENSITY | CALCIUM-SENSING RECEPTOR | HUMAN OSTEOBLASTIC CELLS | OSTEOPROTEGERIN LIGAND | CATHEPSIN-K INHIBITOR | STRONTIUM RANELATE | VERTEBRAL FRACTURE | HEALTHY POSTMENOPAUSAL WOMEN | FRACTURE RISK | Wnt Proteins - drug effects | Vitamin D Deficiency - complications | Calcium - metabolism | Bone Morphogenetic Proteins - immunology | Humans | Middle Aged | Osteoporosis - diagnosis | Osteoporosis, Postmenopausal - metabolism | Antibodies, Monoclonal - therapeutic use | Osteoporosis - drug therapy | Wnt Proteins - metabolism | Biphenyl Compounds - therapeutic use | Osteoporosis - etiology | Bone Remodeling - drug effects | Antibodies, Monoclonal, Humanized | Osteoporosis - metabolism | Vitamin D Deficiency - therapy | Aged, 80 and over | Bone Resorption - metabolism | Diphosphonates - therapeutic use | Female | Benzodioxoles - therapeutic use | RANK Ligand - therapeutic use | Anabolic Agents - therapeutic use | Osteoporosis - prevention & control | Risk Assessment | Osteoporotic Fractures - prevention & control | Risk Factors | Bone Resorption - drug therapy | Bone Density Conservation Agents - therapeutic use | Denosumab | Absorptiometry, Photon | Genetic Markers - immunology | Osteoclasts - metabolism | Osteoporosis, Postmenopausal - drug therapy | Randomized Controlled Trials as Topic | Bone Density - drug effects | Quinazolines - therapeutic use | Aged | Osteoblasts - metabolism | Intercellular Signaling Peptides and Proteins - immunology | Osteoporosis | Complications and side effects | Care and treatment | Diagnosis | Bones | Vitamin D | Womens health | Metabolic disorders | Cathepsin K | Cytokines | Proteinase | Socio-economic aspects | SOST protein | Osteoblasts | Post-menopause | Bone resorption | NF- Kappa B protein | Bone mass | Fractures | Reviews | Aging | Monoclonal antibodies | Osteoclasts | Dkk1 protein | Osteogenesis | Communication
Journal Article